It has no completed human clinical trials measuring fat loss outcomes, and it is not FDA-approved for weight management or any other therapeutic use
When semaglutide activates GLP-1 receptors on pancreatic beta cells, those cells immediately sense blood glucose levels more acutely and release insulin only when glucose is elevatedpreventing the harmful blood sugar spikes that occur after meals
Front Cell Dev Biol , 10 , 954099
Short form: reduces other cravings as well as food cravings
Risk factors for developing blood clots include having a history of DVT or pulmonary embolism, long periods of sitting or bed rest, such as during long flights or hospital stays, being overweight, having a family history of blood clots or clotting disorders, having inherited conditions like Factor V Leiden mutation, being over 60 years of age, or having diabetes